Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer

Petros D. Grivas, Diane M. Robins, Maha Hussain*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations

Abstract

Androgen deprivation is the cornerstone of the management of metastatic prostate cancer. Despite several decades of clinical experience with this therapy there are no standard predictive biomarkers for response. Although several candidate genetic, hormonal, inflammatory, biochemical, metabolic biomarkers have been suggested as potential predictors of response and outcome, none has been prospectively validated nor has proven clinical utility to date. There is significant heterogeneity in the depth and duration of hormonal response and in the natural history of advanced disease; therefore to better optimize/individualize therapy and for future development, identification of biomarkers is critical. This review summarizes the current data on the role of several candidate biomarkers that have been evaluated in the advanced/metastatic disease setting.

Original languageEnglish (US)
Pages (from-to)82-93
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume85
Issue number1
DOIs
StatePublished - Jan 2013

Keywords

  • Androgen deprivation therapy (ADT)
  • Androgen receptor (AR)
  • Androgens
  • Hormonal therapy
  • Predictive biomarkers
  • Prognostic biomarkers
  • Prostate cancer
  • Prostate-specific antigen (PSA)

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this